FDA Grants Orphan Designation for Galidesivir in Marburg
Filed with ASX · · 2 pages · English
Summary by 6ix AI
Island Pharmaceuticals Ltd has announced that the US FDA has granted Orphan Drug Designation to Galidesivir for the post-exposure prophylaxis of Marburg virus disease, marking a significant regulatory milestone for the program. This designation enhances the regulatory and commercial positioning of Galidesivir, providing potential benefits such as market exclusivity and exemption from certain FDA fees. The company is advancing Galidesivir towards potential approval and commercialization, following strong progress in manufacturing and regulatory activities.
Written by 6ix AI from the company’s filing. How 6ix writes summaries
Island Pharmaceuticals Ltd on 6ix
In the deck
Story so far
Earlier from Island Pharmaceuticals
- Investor Presentation - Asia Dengue Summit
- Investor presentation
- Island Secures USAMRIID Support for Galidesivir Study
- Island Advances Galidesivir GMP Manufacturing for Biodefence
- Island Adds Biodefence Leader as Filovirus Risks Escalate
Later from Island Pharmaceuticals
- Singapore Patent Expands Island's ISLA 101 Viral Protection
- Pause in Trading
- Galidesivir approved for treatment use in in Ebola epidemic
- Investor Presentation - Ebola Clinical Program
- Texas Biomed SOW accelerates pivotal FDA pathway
Follow Island Pharmaceuticals into a list and get an email when it puts out news.
Follow Island Pharmaceuticals